Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

Journal of the National Cancer Institute

Volumn 89, Issue 2, 1997, Pages 139-147

  Gasparini, Giampietro ^a   Toi, Masakazu ^b   Gion, Massimo ^c   Verderio, Paolo ^d   Dittadi, Ruggero ^c   Hanatani, Mitsuya ^e   Matsubara, Isamu ^e   Vinante, Orazio ^f   Bonoldi, Emanuela ^a   Boracchi, Patrizia ^d   Gatti, Carlo ^c   Suzuki, Hideo ^e   Tominaga, Takeshi ^b  

^a St Bortolo Medical Centre   (Italy)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c Regional Medical Centre   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Toagosei Co   (Japan)

^f Medical Oncology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER SURVIVAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0031032073     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.2.139     Document Type: Article

References (54)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis [see comment citation in Medline]. Cell 1994; 79:185-8.
3. Folkman J. Clinical applications of research on angiogenesis [see comment citations in Medline]. N Engl J Med 1995;333:1757-63.
4. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery [see comment citation in Medline]. Lancet 1995;346:1334-5.
5. Rak J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis. Eur J Cancer 1996;32A:2438-50.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
7. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
8. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
9. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996;97:469-76.
10. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
11. Detmar M, Brown L, Claffey KB, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 1994;180:1141-6.
12. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62.
13. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
14. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, et al. Upregulation of vascular endothelial growth factor (VEGF) and down-regulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11:1569-79.
15. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87: 506-16.
16. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995;1:961-4.
17. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045-9.
18. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
19. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
20. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24.
21. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108(Pt 6):2369-79.
22. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996;32A: 2413-22.
23. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:213-9.
24. Potgens AJ, van Altena MC, Lubsen NH, Ruiter DJ, de Waal RM. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol 1996;148:1203-17.
25. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-82.
26. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma [see comment citation in Medline]. J Clin Oncol 1994;12:454-66.
27. Obermair A, Kurz C, Czerwenka K, Thoma M, Kaider A, Wagner T, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 1995;62:126-31.
28. Ellis LM, Fidler IJ. Angiogenesis and breast cancer metastasis [see comment citation in Medline]. Lancet 1995;346:388-90.
29. American Joint Committee on Cancer. Manual for staging breast carcinoma. 3rd ed. 1989.
30. Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer 1948;2:7-15.
31. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
32. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975;36:1-85.
33. Hanatani M, Tanaka Y, Kondo S, Ohmori I, Suzuki H. Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/ vascular permeability factor in human serum. Biosci Biotech Biochem 1995;59:1958-9.
34. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996;77:1101-6.
35. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
36. Hollander M, Wolfe DA. Test designed to detect broad alternatives. In: Hollander M, Wolfe DA, editors. Nonparametric statistical methods. Chapter 10. New York: John Wiley & Sons, 1973;219-28.
37. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors [see comment citations in Medline]. J Natl Cancer Inst 1994;86:829-35.
38. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61.
39. Therneau TM, Grambsch PM, Flemming TR. Martingale-based residuals for survival models. Biometrika 1990;77:146-60.
40. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, et al. Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-6.
41. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers [see comment citation in Medline]. J Natl Cancer Inst 1994;86:356-61.
42. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [see comment citation in Medline]. N Engl J Med 1994;331:1480-7.
43. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
44. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;59:5814-9.
45. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996; 271:1079-80.
46. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels [see comment citation in Medline]. Lab Invest 1993;69:508-17.
47. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996;132:1177-88.
48. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
49. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
50. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-30.
51. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
52. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2: 689-92.
53. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 1996;7: 441-4.
54. Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer 1996;32A:2379-85.